Navigation Links
Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date:10/14/2008

Additional Data Presentation Shows Encouraging 12-Month Outcomes from Single- Center Study Involving Patients with Predominantly Complex Lesions

WASHINGTON, Oct. 14 /PRNewswire/ -- OrbusNeich today announced that an interim analysis of 12-month follow-up data from the global e-HEALING registry show good safety and efficacy in the real-world use of the company's Genous Bio-engineered R stent.

Presented by Professor Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2008, in Washington, D.C., the data from 3,200 patients were a target lesion revascularization (TLR) rate of 5%, a subacute thrombosis (SAT) rate of 0.4%, a late stent thrombosis (LST) rate of 0.3%, and a major adverse cardiac events (MACE) rate of 8.5%.

"The data further support the use of Genous as an alternative to drug- eluting stents, especially in light of the relatively minimal dual- antiplatelet therapy requirements with the stent," said de Winter, a co- principal investigator of the study. "Patient compliance with extended dual- antiplatelet therapy due to cost and other factors such as patients facing imminent non-cardiac surgery are issues that we can address by using Genous."

OrbusNeich's e-HEALING clinical study is a multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients treated with the Genous Bio-engineered R stent. The study protocol recommends that patients receive one month of clopidogrel treatment after the procedure. Clinical follow-up takes place at 30 days, six months and 12 months. The primary endpoint of the registry is target vessel failure at 12 months.

In a related presentation at TCT 2008, de Winter and his colleagues reported data from the Academic Medical Center's single-center, real-world study of the Genous stent in patients with predominantly complex lesions. The data, presented in an electronic pos
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
2. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
3. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
4. Fralex provides update on timing of interim analysis results
5. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
6. Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting
7. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
8. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
9. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
10. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
11. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
(Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
(Date:8/28/2015)... Aug. 28, 2015  Today, in final recognition of ... Lens Health Week, 1-800 Contacts is sharing how to ... contact lens wearers who do not properly care for ... eye infections. Most contact lens wearers ... a clean lens case is sometimes overlooked.  When proper ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Investigation Report on China's Pranoprofen Market, 2010-2019 21-800 Contacts Shares Tips on How to Clean Lens Cases 2
... Conn., Sept. 12, 2011 Breast Imaging ... can now benefit from the exceptional image quality of ... from FUJIFILM Medical Systems U.S.A., Inc. Now FDA 510(k) ... extraordinary detail of potential abnormalities that not only assists ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... LLY ) and Alkermes, Inc. (Nasdaq: ... DURATION-3 and -4 trials demonstrating patients treated with ... suspension) experienced significant improvements in select cardiovascular risk ...
Cached Medicine Technology:Fujifilm's Aspire HD Receives FDA Clearance 2Fujifilm's Aspire HD Receives FDA Clearance 3Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 2Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 3Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 4Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 5Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 6Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 7Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 8Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 9
(Date:8/28/2015)... TX (PRWEB) , ... August 28, 2015 , ... For ... Center is taking part with their subsidiary USPI Tenet Health. , The American Heart ... fight heart disease and stroke. They believe that together, a difference can be made. ...
(Date:8/28/2015)... Hanover, MA (PRWEB) , ... August 28, 2015 , ... ... benefitting the renowned Brain Aneurysm Foundation has added yet another accolade to its ... Chicago, Rahm Emanuel. , “With the help of the medical community and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... high grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in ... finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged ...
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... learn whether protein supplements and cycling during treatments can ... function, thanks to a $2.1 million grant from the ... failure face many health problems. They are at high ... and they also develop a peculiar condition called vascular ...
... a model of stroke A team of researchers, led ... identified a way to preserve nerve cells in a rat model ... of oxygen to part of the brain as a result of ... leads to nerve cell death, although the exact mechanisms underlying ischemic ...
... shoulder muscles in elderly patients is often discouraged because of ... Rush University Medical Center has shown that minimally invasive, or ... study has just been published online in Arthroscopy: ... appear in the October issue. "In people over the ...
... study of Ewing,s sarcoma that screened hundreds of genes based ... anti-cancer drug targets, according to a scientific paper by the ... journal Molecular Cancer . Ewing,s sarcomas are rare, ... bones of teenagers. They represent nearly 3 percent of all ...
... the probability of dying in road accidents on the basis ... Their conclusions are clear reducing the time between an ... from 25 to 15 minutes would cut the risk of ... until the emergency medical services arrive is 25 minutes in ...
... Faith based schools are on the rise in ... values at odds with legislation on equality? Research that ... Leadership published by SAGE shows what happens when school ... consequences for gay students and staff. The UK ...
Cached Medicine News:Health News:Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out 2Health News:Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out 3Health News:JCI online early table of contents: Sept. 1, 2010 2Health News:JCI online early table of contents: Sept. 1, 2010 3Health News:JCI online early table of contents: Sept. 1, 2010 4Health News:JCI online early table of contents: Sept. 1, 2010 5Health News:JCI online early table of contents: Sept. 1, 2010 6Health News:Surgery to repair torn shoulder muscles in the elderly can reduce pain and improve function 2Health News:TGen finds therapeutic targets for rare cancer in children 2Health News:10 minutes could prevent one-third of road deaths 2Health News:Keeping faith -- schools must balance ethos with equality 2
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: